TABLE 5.
Inhibitory Compound | Yeast Transformant |
||
---|---|---|---|
pPIC3.5K-hPept1 | pPIC3.5K-mPept1 | pPIC3.5K-rPept1 | |
Control | 100 ± 28 | 100 ± 7 | 100 ± 10 |
Glycine | 130 ± 17 | 104 ± 6 | 91.5 ± 6.4 |
l-Histidine | 122 ± 13 | 103 ± 6 | 113 ± 8 |
GlyPro | 3.9 ± 1.7* | 1.9 ± 1.0* | 0.6 ± 0.3* |
Cefadroxil | 6.4 ± 13.7* | 16.7 ± 1.7* | 23.1 ± 1.2* |
Cephradine | 23.2 ± 5.4* | 9.8 ± 0.7* | 23.4 ± 1.8* |
Cefazolin | 81.1 ± 2.6 | 87.4 ± 0.7 | 93.7 ± 6.3 |
Cephalothin | 84.8 ± 3.3 | 85.0 ± 4.6 | 119 ± 1 |
Cephapirin | 100 ± 14 | 83.7 ± 6.3 | 122 ± 5 |
Acyclovir | 114 ± 8 | 99.8 ± 5.6 | 109 ± 10 |
Valacyclovir | 3.5 ± 3.3* | 4.5 ± 1.1* | 5.5 ± 0.5* |
SITS | 127 ± 12 | 86.1 ± 3.6 | 107 ± 10 |
TEA | 113 ± 9 | 83.7 ± 2.0 | 94.8 ± 5.4 |
Elacridar | 100 ± 6 | 89.3 ± 3.6 | 119 ± 3 |
p ≤ 0.001 compared with control. GlySar was studied at 5.0 μM and the potential inhibitors at 10 mM.